Tania Rodrigues
Chimeric antigen receptor (CAR)-T continues to take centre stage as a paradigm shift in the treatment of cancer. The phrase ‘paradigm shift’ gets thrown about a lot in the discussion of new developments in medicine, but when it comes to CAR-T therapies we believe that it is really justified in this case, due to their potential to be transformative – as evidenced by Gilead’s December 2021 announcement that Yescarta shows durable long-term survival in patients with refractory large B-cell lymphoma.
However, will market access and hospital processes also need to transform to accommodate these therapies? In this
issue of Free Thinking, we take a look.
Chimeric antigen receptor (CAR)-T continues to take centre stage as a paradigm shift in the treatment of cancer. The phrase ‘paradigm shift’ gets thrown about a lot in the discussion of new developments in medicine, but when it comes to CAR-T therapies we believe that it is really justified in this case, due to their potential to be transformative – as evidenced by Gilead’s December 2021 announcement that Yescarta shows durable long-term survival in patients with refractory large B-cell lymphoma.
However, will market access and hospital processes also need to transform to accommodate these therapies? In this
issue of Free Thinking, we take a look.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.